Soligenix (NASDAQ:SNGX) & Ainos (NASDAQ:AIMD) Financial Contrast

Ainos (NASDAQ:AIMD) and Soligenix (NASDAQ:SNGX) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their earnings, dividends, profitability, institutional ownership, risk, analyst recommendations and valuation.

Earnings and Valuation

This table compares Ainos and Soligenix’s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ainos	$120,000.00	53.73	-$13.77 million	($2.55)	-0.41
Soligenix	$840,000.00	5.04	-$6.14 million	($0.90)	-0.45

Soligenix has higher revenue and earnings than Ainos. Soligenix is trading at a lower price-to-earnings ratio than Ainos, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

Ainos has a beta of 1.47, meaning that its share price is 47% more volatile than the S&P 500. Comparatively, Soligenix has a beta of 1.93, meaning that its share price is 93% more volatile than the S&P 500.

Analyst Recommendations

This is a summary of recent ratings and target prices for Ainos and Soligenix, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ainos	0	0	0	0	N/A
Soligenix	0	0	0	0	N/A

Soligenix has a consensus target price of $3.00, suggesting a potential upside of 635.29%. Given Soligenix’s higher probable upside, analysts plainly believe Soligenix is more favorable than Ainos.

Institutional & Insider Ownership

3.6% of Soligenix shares are held by institutional investors. 4.6% of Ainos shares are held by company insiders. Comparatively, 1.4% of Soligenix shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Profitability

This table compares Ainos and Soligenix’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Ainos	-11,205.49%	-47.96%	-40.37%
Soligenix	-731.94%	-251.07%	-49.94%

Summary

Soligenix beats Ainos on 7 of the 12 factors compared between the two stocks.

About Ainos

Ainos, Inc., a healthcare company, engages in developing medical technologies for point-of-care testing and safe and novel medical treatment for disease indications. The company offers COVID-19 antigen rapid test kit and Ainos' cloud-based test management App, a cloud-based test management platform comprising an antigen rapid test kit, a personal application, and an enterprise app; COVID-19 nucleic acid test; volatile organic compounds point-of-care testing; Very Low-Dose Oral Interferon Alpha, a low-dose oral interferon alpha formulation based IFN-a's broad treatment applications; and Synthetic RNA developing a SRNA technology platform in Taiwan. It also provides women's health, pneumonia, Ainos Pen, AI Nose, and other products. Ainos, Inc. was formerly known as Amarillo Biosciences, Inc. and changed its name to Ainos, Inc. in May 2021. The company was incorporated in 1984 and is based in San Diego, California.

About Soligenix

Soligenix, Inc., a late-stage biopharmaceutical company, focuses on developing and commercializing products to treat rare diseases in the United States. The company operates through two segments, Specialized BioTherapeutics and Public Health Solutions. The Specialized BioTherapeutics segment develops SGX301 (HyBryte), a novel photodynamic therapy, which has completed Phase III clinical trial for the treatment of cutaneous T-cell lymphoma; SGX942, an innate defense regulator technology that is in Phase III clinical trial for the treatment of inflammatory diseases, including oral mucositis in head and neck cancer; SGX302, an IDR technology which is in Phase IIa study to treat mil-to-moderate Psoriasis; and SGX945 and IDR technology that is in Phase IIa protocol for the treatment of Aphthous Ulcers in Behçet's Disease. The Public Health Solutions segment is involved in the development of RiVax, a ricin toxin vaccine candidate, which has completed Phase Ia, Ib, and Ic clinical trials; SGX943, a therapeutic candidate that is in pre-clinical stage for the treatment of antibiotic-resistant and emerging infectious diseases; ThermoVax, a technology in pre-clinical development for thermostabilizing vaccines; and CiVax, a vaccine candidate for the prevention of COVID-19. The company was formerly known as DOR BioPharma, Inc. and changed its name to Soligenix, Inc. in 2009. Soligenix, Inc. was incorporated in 1987 and is headquartered in Princeton, New Jersey.